- Home
- AMC vs ANL Comparison
AMC vs ANL Comparison
Compare AMC & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMC | ANL |
|---|---|---|
| Founded | 1920 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 786.8M | 703.3M |
| IPO Year | 2007 | 2022 |
Fundamental Metrics
Financial Performance| Metric | AMC | ANL |
|---|---|---|
| Price | $1.61 | $12.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $2.03 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 33.5M | 637.3K |
| Earning Date | 05-05-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,848,900,000.00 | N/A |
| Revenue This Year | $11.41 | $36.02 |
| Revenue Next Year | $5.18 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.57 | N/A |
| 52 Week Low | $0.93 | $0.88 |
| 52 Week High | $4.08 | $17.25 |
Technical Indicators
Market Signals| Indicator | AMC | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 60.93 | 50.99 |
| Support Level | $1.44 | $6.92 |
| Resistance Level | $1.79 | $17.25 |
| Average True Range (ATR) | 0.15 | 2.51 |
| MACD | 0.00 | -0.17 |
| Stochastic Oscillator | 49.23 | 51.54 |
Price Performance
Historical ComparisonAbout AMC AMC Entertainment Holdings Inc.
AMC Entertainment Holdings Inc is involved in the theatrical exhibition business. The company owns, operates, or has interests in theatres located in the United States and Europe. It provides amenities such as plush, power recliners, MacGuffins full bars, AMC Dine-In Theatres, and premium presentation. The company has identified two reportable segments and reporting units for its theatrical exhibition operations, U.S. markets and International markets. It derives key revenue from the U.S.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.